Sign inJoin waitlistJoin the waitlist

Marc Bonaca

Executive Director- CPC Clinical Research

Credentials: · · ·

History

School of Medicine
Present

Brigham and Women's Hospital Program
Until 2004
University of Connecticut School of Medicine
2003

Research

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2019 · 4,800 citations
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome…
Systematic review or meta-analysis · The Lancet · 2019 · 2,153 citations
Long-term use of ticagrelor in patients with prior myocardial infarction
New England Journal of Medicine · 2015 · First of 26 authors · 1,516 citations

MS
Marc Sabatine
89 papers
EB
Eugene Braunwald
69 papers
DM
David Morrow
67 papers
Deepak Bhatt
62 papers
BS
Benjamin Scirica
52 papers
Connie Hess
47 papers
Judith Hsia
40 papers
SW
Stephen Wiviott
40 papers
Manesh Patel
37 papers
Mark Nehler
34 papers
Mark Creager
25 papers
LH
Lloyd Haskell
24 papers

Grants

Proteomics, Outcomes and Precision Treatment of Patients with Chronic Limb Threatening Ischemia (CLTI).
National Heart, Lung, and Blood Institute · R01
PI · $872.8K · New York University School of Medicine
2026–2030
KidsDOTT-DCC
National Heart, Lung, and Blood Institute · U01
Contact PI · $366.1K · University of Colorado Denver
2016–2023

Clinical trials

Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
Principal investigator · Recruiting
Colorado Prevention Center
2025–2027
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Principal investigator · Recruiting · Phase 4
Duke University
2025–2029
Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Principal investigator · Completed · Phase 2, Phase 3
ARCA Biopharma, Inc.
2020–2022